Abstract
Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.
MeSH terms
-
Administration, Oral
-
Aged
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / secondary
-
ErbB Receptors / antagonists & inhibitors
-
Erlotinib Hydrochloride
-
Female
-
Humans
-
Liver Failure, Acute / chemically induced*
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / pathology
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects*
Substances
-
Protein Kinase Inhibitors
-
Quinazolines
-
Erlotinib Hydrochloride
-
ErbB Receptors